Curated News
By: NewsRamp Editorial Staff
October 06, 2026
Quantum BioPharma Advances Phase 2 MS Trial with Thermo Fisher Partnership
TLDR
- Quantum BioPharma's Phase 2 Lucid-MS trial for multiple sclerosis with Thermo Fisher positions QNTM ahead in first-in-class neuroprotection.
- Quantum BioPharma's Phase 2 trial will evaluate Lucid-MS's efficacy, safety, and tolerability in progressive MS via PAD2 inhibition.
- Quantum BioPharma's Phase 2 trial of Lucid-MS aims to bring a neuroprotective therapy to people with progressive multiple sclerosis.
- Quantum BioPharma's Lucid-MS targets PAD2, an enzyme linked to myelin degradation, potentially halting multiple sclerosis progression.
Impact - Why it Matters
This news matters because it signals tangible progress in developing a novel treatment for progressive multiple sclerosis, a debilitating disease with few effective therapies. By targeting PAD2 to prevent myelin degradation, Lucid-MS offers a potentially first-in-class approach that could not only slow but possibly reverse MS progression. The partnership with Thermo Fisher's PPD clinical research business brings world-class expertise to the trial, increasing the likelihood of successful execution. For the estimated 2.8 million people worldwide living with MS, this trial represents a beacon of hope for a better future. Investors in Quantum BioPharma also have reason to be optimistic, as a successful trial could unlock significant value and validate the company's innovative pipeline.
Summary
Quantum BioPharma (NASDAQ: QNTM) has taken a critical step forward in its fight against multiple sclerosis (MS) by signing a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific. This agreement sets the stage for the implementation of Quantum's Phase 2 clinical trial of Lucid-21-302, also known as Lucid-MS, following the FDA's clearance to proceed. Thermo Fisher will provide comprehensive support for study start-up and related clinical research services through its PPD™ Clinical Research Business, leveraging its extensive expertise to help advance this promising therapy.
The upcoming randomized, double-blind, placebo-controlled Phase 2 trial will rigorously evaluate the efficacy, safety, and tolerability of Lucid-MS in patients with progressive forms of MS, utilizing both clinical and radiological endpoints. Lucid-MS is an investigational first-in-class New Chemical Entity designed to deliver neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. This mechanism holds potential to prevent and reverse myelin damage, the underlying cause of MS, which could be a game-changer for patients with limited treatment options.
Quantum BioPharma is a biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on advancing Lucid-MS. Beyond MS, Quantum invented UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake (as of March 31, 2026) and stands to receive royalty payments of 7% of sales until reaching $250 million, then 3% in perpetuity. The company also retains full rights to develop similar products for pharmaceutical and medical uses. For more details, visit https://ibn.fm/CZH9U. Investors can stay updated on QNTM news at https://ibn.fm/QNTM. This announcement was distributed by BioMedWire, a specialized communications platform under the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Advances Phase 2 MS Trial with Thermo Fisher Partnership
